We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

19 May 2026 - 22 May 2026
17 Jun 2026 - 19 Jun 2026

Partnership to Advance Proton Therapy Training, Research, and Development

By HospiMedica staff writers
Posted on 04 Mar 2008
A recent agreement made by a group of proton therapy treatment centers and a U.S. More...
university will provide advanced training programs and accredit medical professionals in proton therapy--an alternative to conventional radiation therapy that avoids many of the side effects inherent in the treatment. The agreement focuses on expanding research on the technology to be used for the delivery of proton therapy and developing new protocols using protons to treat a wider range of cancer tumors.

Protons are currently used primarily to treat base-of-skull tumors, ocular melanoma, sinus tumors, pediatric cancers, and prostate cancer. As more centers are developed and the capacity to handle patients increases, ProCure Treatment Centers, Inc. (Bloomington, IN, USA) and the University of Pennsylvania's (U-Penn) Roberts Proton Therapy Center (Philadelphia, PA, USA) agreed to establish new clinical studies to assess the use of protons in areas such as proton therapy in combination with chemotherapy and the improved results obtained from increasing the dose delivered to the tumor. ProCure's network of proton therapy centers will significantly increase the number of patients that can potentially be enrolled in studies. The U-Penn Center will provide oversight, establish data collection procedures, analyze data, and work through any necessary regulatory process.

It is anticipated that within the next five years, at least 10 new proton therapy facilities will open in the United States, including the Roberts Proton Therapy Center and several centers under development by ProCure, resulting in a significant need for trained staff at all levels. The U-Penn Center and ProCure intend to collaborate on setting standards for proton therapy education and training, and to offer accreditation in the field. Training programs are slated to be provided at the ProCure Training and Development Center (TDC), the world's first training center dedicated exclusively to proton therapy. The 1,858-square meter training facility is located in Bloomington, IN, USA. The TDC simulates a working proton therapy center and plans to provide training for radiation oncologists, medical physicists, dosimetrists, radiation therapists, and other staff.

ProCure is working with community hospitals and local radiation oncology practices to open proton centers across the United States. ProCure has a center under construction in Oklahoma and one planned for Illinois. When it opens in summer 2009, the Roberts Proton Therapy Center will be the largest and most comprehensive proton therapy facility in the world, and only the sixth operating proton therapy center in the United States.

Nearly 50,000 cancer patients worldwide have taken advantage of the technology to effectively treat most common types of solid tumor cancers, including head and neck, prostate, breast, lung, colorectal and brain tumors. Proton therapy's ability to precisely target tumors makes it suitable for treating tumors near vital organs, especially in children. It has been shown to reduce normal tissue damage, side effects, and to lessen the probability of secondary tumors later in life.

In the United States, proton therapy is currently only available in five major academic centers.


Related Links:
ProCure Treatment Centers
University of Pennsylvania's Roberts Proton Therapy Center

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Resorbable Bovine Collagen Membrane
GenDerm
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: In a new clinical study, the Camstent Coated Catheter was shown to reduce CAUTIs and antibiotic use compared with standard care (photo courtesy of Camstent)

Bacteria-Resistant Urinary Catheter Coating Reduces Infections and Antibiotic Use

Catheter-associated urinary tract infections (CAUTIs) are a major hospital-acquired infection, responsible for about 75% of urinary tract infections acquired in hospitals. They increase morbidity and drive... Read more

Surgical Techniques

view channel
Image: Six-month FlexPulse IDE data show positive outcomes with Abbott’s TactiFlex Duo catheter, confirming safety and efficacy seen in the CE Mark study for complex AFib (photo courtesy of Abbott)

Dual-Energy Ablation and Conduction System Pacing Show Positive Early Outcomes

Atrial fibrillation and other arrhythmias are common in both hospitalized and ambulatory patients, often complicating hemodynamic stability, stroke prevention, and perioperative care. Within this context,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.